Articles Referencing GERN

Neuralstem: Anticipating More Efficacy Data From ALS Trial And Update On New Clinical Trials

5/7/2013, 2:07 pm from SeekingAlpha in Investing, Stocks

By Smith On Stocks : Investment Opinion and Thesis CUR As will be discussed in this report, the first part of the phase I study in ALS allowed a meaningful evaluation of efficacy in... Read >>

Geron Narrows Loss; Cuts Jobs - Analyst Blog

4/29/2013, 10:03 am from Zacks.com in Investing, Business, Stocks

Geron Corporation ( GERN ) posted a net loss of 9 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 8 cents but narrower than the year-ago... Read >>

Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU

4/7/2013, 6:06 pm from GuruFocus in Investing

According to GuruFocus Insider Data , these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Independent Bank Group Inc. ( IBTX... Read >>

Lower Loss at Geron - Analyst Blog

3/14/2013, 12:11 pm from Zacks.com in Investing, Business, Stocks

Geron Corporation ( GERN ) posted a net loss of 10 cents per share in the fourth quarter of 2012, narrower than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of... Read >>

After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP

3/12/2013, 2:00 pm from NASDAQ.com News in News Headlines, Earnings

The following companies are expected to report earnings after hours on 03/12/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Kennedy-Wilson Holdings Inc. ( ... Read >>

Geron's Update on Stem Cell Assets - Analyst Blog

1/10/2013, 2:00 pm from Zacks.com in Investing, Business, Stocks

Geron Corporation ( GERN ) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. ( BTX ) and BioTime's recently formed subsidiary, BioTime... Read >>

Buy or Sell? Monday's Losers: TITN, GERN

9/10/2012, 9:15 am from David Sterman in Investing, Stocks

Among the biggest losers in Monday's early trading are Titan Machinery (Nasdaq: TITN) and Geron (nasdaq: GERN). The drought of 2012 is just starting to show up in quarterly reports, and... Read >>

Stem Cell Therapy May Prevent Heart Failure: 4 Companies to Watch

11/16/2011, 8:00 pm from Kapitall in Investing, Investing Ideas, Stocks, Technology

( Written by Alexander Crawford. Data sourced from Finviz.) A stem cell treatment for heart disease from Australia’s biotech firm Mesoblast Ltd lowered the risk of heart attack or cardiac... Read >>

Medical Breakthrough: Successful Stem Cell Transplant in Sweden

7/8/2011, 5:11 pm from Kapitall in Investing, Investing Ideas, Stocks

Finding organ donors could soon be a thing of the past. The latest miracle of modern medicine allowed doctors to replace a man’s cancerous windpipe with a new man-made one, comprised of a... Read >>

8 Cash-Comfortable Stocks Under $5

6/7/2011, 1:31 pm from Kapitall in Investing, Investing Ideas, Stocks

Lower-priced stocks may look attractively valued, but they often belong to very young companies with a short or non-existent history of operations. One way to pick the better from the worse is by... Read >>

Momentum Ideas: 15 Undervalued Stocks Approaching An Inflection Point

11/22/2010, 1:24 pm from Kapitall in Investing, Investing Ideas

Compiled by Eben Esterhuizen, CFA: The following is a list of stocks that are approaching an inflection point, based on moving average trends. For this article, we define an inflection point as... Read >>

Geron: Buyer Beware

10/13/2010, 3:45 am from SeekingAlpha in Investing, Technology

In recent days, shares of biopharma company Geron ( GERN ) have gone viral, up over 20% in a week. News of a clinical trial for an embryonic stem cell therapy aimed at spinal cord... Read >>

Joe Feshbach's Highest Conviction Position: A Regenerative Medicine 'Game Changer'

1/12/2010, 3:49 am from SeekingAlpha in Investing, Technology, Stocks

Joe Feshbach submits: Joseph L. Feshbach has over 25 years of professional investment experience, using both long and short equity strategies. Additionally he has been Chairman and CEO of... Read >>